Aethlon Medical Basic EPS 2010-2024 | AEMD

Aethlon Medical basic eps from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
Aethlon Medical Annual Basic EPS
2024 $-4.86
2023 $-5.86
2022 $-7.10
2021 $-6.50
2020 $-18.70
2019 $-51.30
2018 $-68.97
2017 $-140.93
2016 $-98.95
2015 $-182.91
2014 $-515.74
2013 $-224.89
2012 $-599.70
2011 $-599.70
2010 $-599.70
2009 $-1,049.48
Aethlon Medical Quarterly Basic EPS
2024-09-30 $-0.20
2024-06-30 $-0.34
2024-03-31 $-0.92
2023-12-31 $-1.37
2023-09-30 $-1.22
2023-06-30 $-1.35
2023-03-31 $-0.88
2022-12-31 $-1.24
2022-09-30 $-1.84
2022-06-30 $-1.90
2022-03-31 $-2.60
2021-12-31 $-1.60
2021-09-30 $-1.30
2021-06-30 $-1.60
2021-03-31 $-1.50
2020-12-31 $-2.00
2020-09-30 $-1.50
2020-06-30 $-1.50
2020-03-31 $13.30
2019-12-31 $-2.80
2019-09-30 $-12.90
2019-06-30 $-16.30
2019-03-31 $-13.91
2018-12-31 $-16.70
2018-09-30 $-11.70
2018-06-30 $-9.00
2018-03-31 $-4.50
2017-12-31 $-11.99
2017-09-30 $-20.99
2017-06-30 $-31.48
2017-03-31 $-32.98
2016-12-31 $-22.49
2016-09-30 $-43.48
2016-06-30 $-41.98
2016-03-31 $-23.99
2015-12-31 $-23.99
2015-09-30 $-23.99
2015-06-30 $-26.99
2015-03-31 $0.00
2014-12-31 $-38.98
2014-09-30 $-23.99
2014-06-30 $-119.94
2014-03-31 $-290.86
2013-12-31 $-74.96
2013-09-30 $-149.93
2013-06-30 $0.00
2013-03-31 $-74.96
2012-12-31 $0.00
2012-09-30 $-74.96
2012-06-30 $-74.96
2012-03-31 $-299.85
2011-12-31 $-74.96
2011-09-30 $0.00
2011-06-30 $-224.89
2011-03-31 $299.85
2010-12-31 $-224.89
2010-09-30 $-299.85
2010-06-30 $-374.81
2010-03-31 $-149.93
2009-12-31 $-224.89
2009-09-30 $-74.96
2009-06-30 $-149.93
2009-03-31 $-149.93
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.006B $0.001B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $543.768B 21.87
Cigna Group (CI) United States $91.359B 11.95
Humana (HUM) United States $35.896B 16.34
Centene (CNC) United States $30.479B 8.94
Molina Healthcare (MOH) United States $16.633B 13.23
Select Medical Holdings (SEM) United States $5.136B 17.79
Joint (JYNT) United States $0.176B 106.82